PBYI - NASDAQ
Puma Biotechnology, Inc.
$6.83
-2.2%Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
At a Glance
Live Snapshotpbyi
Total Assets
Last Annual Value
216.30M
3-Year CAGR
-1%
5-Year CAGR
-2%
10-Year CAGR
-1%
Puma Biotechnology, Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Puma Biotechnology, Inc. NASDAQ:PBYI | 216.30M | -2.1% | -0.9% | -1.5% | |
 Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | 271.15M | -14.2% | -7.1% | 18.1% | |
 Humacyte, Inc. NASDAQ:HUMA | 116.37M | -3.2% | -16.5% | N/A | |
 Sagimet Biosciences Inc. NASDAQ:SGMT | 116.48M | 6.4% | 14.6% | N/A | |
 Voyager Therapeutics, Inc. NASDAQ:VYGR | 252.28M | -10.4% | 5.4% | 2.9% | |
 Atea Pharmaceuticals, Inc. NASDAQ:AVIR | 315.22M | -19.1% | -16.4% | N/A | |
 Cabaletta Bio, Inc. NASDAQ:CABA | 165.08M | -13.3% | 5.5% | N/A | |
 Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | 268.69M | 24.3% | 14.4% | N/A | |
 Tectonic Therapeutic, Inc. NASDAQ:TECX | 261.04M | 87.8% | 51.3% | 47.4% | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 276.56M | -0.1% | -1.0% | N/A | |
 Allogene Therapeutics, Inc. NASDAQ:ALLO | 415.90M | -13.5% | -16.9% | N/A |
Puma Biotechnology, Inc. Fair Value Envelope
Related Guides
Continue your PBYI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.